Pathos AI is an AI and technology company developing drugs. The company redesigns drug development from first principles: identifying clinical assets, making portfolio decisions with continuously updated probability-of-success calculations, and guiding clinical trials with AI-native monitoring. Pathos's pipeline includes clinical-stage programs in metastatic castration-resistant prostate cancer, multiple myeloma, MET-altered non-small-cell lung cancer, ER+/HER2� breast cancer, and TROP2/HER3-expressing solid tumors.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
10/26/26	$237,000,000	Series E	Bristol Myers Squibb	$3,000,000,000